Loading…
← CockpitCompetitor Analysis › 4104.TW Excelsior Medical Co., Ltd.Open in the cockpit ↗

Excelsior Medical Co., Ltd.4104.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Medical Distributors
Momentum leader 81
Mkt cap
$404M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$424,802
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.7 pp
WACC 5.0%
Hurdle
-7 pp
Req g minus delivered
Next earnings
107 days
5 Mar 2027
Close · TWDNT$71.20
1D-0.4%
1W-1.1%
1M-3.6%
3M-0.1%
6M+4.5%
YTD-11.3%
1Y-15.0%
ATR %1.2%
52w lowhigh15.4% off high

What Excelsior Medical does

No business profile yet.

Excelsior Medical at a glance

Size Excelsior Medical (4104.TW) is a Taiwan Health Care company (Medical Distributors) with a market value of $404M, the 513th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$71.20 on 18 Nov 2026.

Performance Over six months the shares gained 4.5%, against -5.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 11.1% over the last twelve months (peer median +2.9%); the operating margin is 7.8% (peer median 1.9%).

Valuation It trades at 1.4× enterprise value to sales against a peer median of 1.1× (7th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.7 points below its cost of capital (5.0% WACC).

Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).

Relative performance

9510010521 May 202621 Aug 202618 Nov 20264104.TW 105Peer median 94
Six months, rebased to 100: Excelsior Medical against the median of its 20 peers (local-currency closes).

Excelsior Medical financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$9.75BNT$8.79BNT$8.54BNT$8.24BNT$7.19B
Revenue growth—+3%+4%+15%—
Gross profitNT$2.02BNT$1.80BNT$1.72BNT$1.62BNT$1.46B
EBITDANT$1.12BNT$1.04BNT$1.05BNT$969MNT$829M
Net incomeNT$905MNT$806MNT$771MNT$747MNT$667M
Free cash flowNT$1.57B-NT$1.27BNT$2.65BNT$178MNT$718M
Capital expenditureNT$133MNT$83.0MNT$121MNT$143MNT$173M
Total debtNT$2.13BNT$2.16BNT$1.43BNT$1.44BNT$808M

Quarterly statements and history in the cockpit →

Excelsior Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%315100007866176037166051363011667447301370000668600628688366ENTEROARJO-B603368DOCM74764104.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Excelsior Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×2×4×3151000078661760371660513630116674473013700006686006282733NEU688366ENTEROARJO-B60336830158474764104.TWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Excelsior Medical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%315100007860513674473013700006686006282733688366ENTERO6033683015844104.TWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Excelsior Medical is the large dot.

Excelsior Medical competitors and peer comparison

How Excelsior Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Excelsior Medical against its 20 peers (data as of 18 Nov 2026)
Measure4104.TWPeer medianRank in peer set
1-month return-3.6%-4.1%10th highest of 21
6-month return+4.5%-5.6%6th highest of 21
Distance from 52-week high-15.4%-22.4%7th highest of 21
Revenue growth (TTM)+11.1%+2.9%5th highest of 21
Operating margin7.8%1.9%5th highest of 21
EV / Sales1.4×1.1×7th most expensive of 21
Growth the price implies (Req g, 7 yrs)-1.2%4.7%6th least demanding of 16
Growth delivered (Del g)+5.7%+6.0%8th lowest of 16
Hurdle (Req g minus delivered)-6.9 pp-5.0 pp6th least demanding of 16
ROIC minus cost of capital-0.7 pp-0.2 pp10th lowest of 21
EV / EBITDA12.5×7.3×most expensive of 4
Net debt / EBITDA-2.4×1.5×2nd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%1.4×-1.2%+5.7%
Vital KSK 3151.TJapan$399M-1%+3%0%0.1×4.7%+2.6%
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%0.6×58.3%-7.8%
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%288.8×n/an/a
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%1.0×n/an/a
Nagaileben 7447.TJapan$319M0%+1%21%1.6×-12.7%-0.4%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Rongfeng 000668.SZChina$297M-32%+61%14%4.8×9.6%+30.0%
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%1.8×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%

Questions

Which companies are Excelsior Medical's closest peers?
The cockpit's peer set: Vital KSK (3151.T), Shenzhen Neptunus Bioengineering (000078.SZ), Gongwin Biopharm (6617.TWO), Thalys Medical Technology (603716.SS), Shanghai Lily & Beauty Cosmetics (605136.SS), Shanghai Universal Biotech (301166.SZ), Nagaileben (7447.T), GKHT Medical Technology (301370.SZ).
Is Excelsior Medical expensive compared with its peers?
On ev / sales it trades at 1.4× against a peer median of 1.1×, 7th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Excelsior Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +4.5% against -5.6% for the median peer; over one year -15.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.